Persons with dispensed medicines; origin
| Sex | Age | Origin | Medicine group (ATC) | Periods | Persons with medicines, relative (%) | Defined daily doses (DDD), relative (number per 1 000 persons) |
|---|---|---|---|---|---|---|
| Total male and female | Total age | Origin country: Europe (excl. NL) | Total | 2022* | 48.19 | 339,582 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A Alimentary tract and metabolism | 2022* | 17.35 | 78,628 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A01 Stomatological preparations | 2022* | 0.47 | 39 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A01A Stomatological preparations | 2022* | 0.47 | 39 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A02 Drugs for acid related disorders | 2022* | 8.48 | 29,573 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A02A Antacids | 2022* | 0.00 | 1 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A02B Drugs for peptic ulcer and gord | 2022* | 8.48 | 29,573 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A02X Oth. drugs for acid related disord. | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A03 Drugs for funct.gastrointest.disord. | 2022* | 1.59 | 850 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A03A Drugs for functional bowel disord. | 2022* | 0.38 | 641 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A03B Belladonna and derivatives, plain | 2022* | 0.02 | 2 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A03C Antispasmodics with psycholeptics | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A03D Antispasmodics with analgesics | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A03E Antispasmodics and anticholinergics | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A03F Propulsives | 2022* | 1.23 | 206 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A04 Antiemetics and antinauseants | 2022* | 0.54 | 48 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A04A Antiemetics and antinauseants | 2022* | 0.54 | 48 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A05 Bile and liver therapy | 2022* | 0.07 | 186 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A05A Bile therapy | 2022* | 0.07 | 186 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A05B Liver therapy, lipotropics | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A05C Bile therapy drugs and lipotropics | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A06 Laxatives | 2022* | 6.01 | 5,019 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A06A Laxatives | 2022* | 6.01 | 5,019 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A07 Anti diarr/intest/infl/infect.agents | 2022* | 0.71 | 2,913 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A07A Intestinal antiinfectives | 2022* | 0.29 | 52 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A07B Intestinal adsorbents | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A07C Electrolytes with carbohydrates | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A07D Antipropulsives | 2022* | 0.09 | 75 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A07E Intestinal antiinflammatory agents | 2022* | 0.34 | 2,786 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A07F Antidiarrheal microorganisms | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A07X Other antidiarrheals | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A08 Antiobesity prep. excl.diet products | 2022* | 0.00 | 1 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A08A Antiobesity prep.excl.diet products | 2022* | 0.00 | 1 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A09 Digestives, incl. enzymes | 2022* | 0.09 | 240 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A09A Digestives, incl. enzymes | 2022* | 0.09 | 240 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A10 Drugs used in diabetes | 2022* | 3.19 | 18,257 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A10A Insulins and analogues | 2022* | 0.99 | 4,845 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A10B Blood glucose lowering drugs, excl. | 2022* | 2.79 | 13,412 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A10X Other drugs used in diabetes | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A11 Vitamins | 2022* | 3.88 | 15,238 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A11A Multivitamins, combinations | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A11B Multivitamins, plain | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A11C Vit A and D, incl.combin.of the two | 2022* | 3.88 | 15,233 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A11D Vitamin B1,and with vit. B6 and B12 | 2022* | 0.01 | 2 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A11E Vitamin B-complex, incl. combinat. | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A11G Ascorbic acid (vitamin C) + combin. | 2022* | 0.00 | 2 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A11H Other plain vitamin preparations | 2022* | 0.00 | 1 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A11J Other vitamin products + combinat. | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A12 Mineral supplements | 2022* | 2.24 | 6,233 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A12A Calcium | 2022* | 2.13 | 6,131 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A12B Potassium | 2022* | 0.11 | 87 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A12C Other mineral supplements | 2022* | 0.03 | 16 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A13 Tonics | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A13A Tonics | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A14 Anabolic agents for systemic use | 2022* | 0.00 | 4 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A14A Anabolic steroids | 2022* | 0.00 | 4 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A14B Other anabolic agents | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A15 Appetite stimulants | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A16 Other aliment.tract/metabol.products | 2022* | 0.01 | 26 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | A16A Oth.aliment.tract and metabol.prod. | 2022* | 0.01 | 26 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B Blood and blood forming organs | 2022* | 9.13 | 32,717 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B01 Antithrombotic agents | 2022* | 7.31 | 21,989 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B01A Antithrombotic agents | 2022* | 7.31 | 21,989 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B02 Antihemorrhagics | 2022* | 0.23 | 49 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B02A Antifibrinolytics | 2022* | 0.17 | 31 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B02B Vitamin k and other hemostatics | 2022* | 0.06 | 18 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B03 Antianemic preparations | 2022* | 2.33 | 10,676 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B03A Iron preparations | 2022* | 1.39 | 444 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B03B Vitamin B12 and folic acid | 2022* | 1.04 | 10,232 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B03X Other antianemic preparations | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B05 Blood substitutes / perfus.solutions | 2022* | 0.18 | 2 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B05A Blood and related products | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B05B Intravenous solutions | 2022* | 0.17 | 2 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B05C Irrigating solutions | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B05D Peritoneal dialytics | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B05X Intravenous solution additives | 2022* | 0.01 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B05Z Hemodialytics and hemofiltrates | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B06 Other hematological agents | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | B06A Other hematological agents | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C Cardiovascular system | 2022* | 14.42 | 109,834 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C01 Cardiac therapy | 2022* | 1.86 | 3,822 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C01A Cardiac glycosides | 2022* | 0.35 | 487 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C01B Antiarrhythmics, class I and III | 2022* | 0.26 | 596 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C01C Cardiac stimulants excl. glycosides | 2022* | 0.27 | 4 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C01D Vasodilators used in card. diseases | 2022* | 1.04 | 2,592 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C01E Other cardiac preparations | 2022* | 0.05 | 143 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C02 Antihypertensives | 2022* | 0.23 | 764 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C02A Antiadren.agents, centrally acting | 2022* | 0.06 | 83 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C02B Antiadren.agents, ganglion-blocking | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C02C Antiadren.agents, peripher. acting | 2022* | 0.17 | 656 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C02D Arteriolar smooth muscle agents | 2022* | 0.00 | 2 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C02K Other antihypertensives | 2022* | 0.01 | 24 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C02L Antihypertensives/diuretics combin. | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C02N Combinations of antihypertensives.. | 2022* | 0.00 | 0 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C03 Diuretics | 2022* | 3.96 | 10,885 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C03A Low-ceiling diuretics, thiazides | 2022* | 2.02 | 3,980 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C03B Low-ceiling diuret.,excl. thiazides | 2022* | 0.26 | 563 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C03C High-ceiling diuretics | 2022* | 1.50 | 5,286 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C03D Potassium-sparing agents | 2022* | 0.83 | 917 |
| Total male and female | Total age | Origin country: Europe (excl. NL) | C03E Diuretics/potassium-sparing agents | 2022* | 0.05 | 139 |
| Source: CBS. | ||||||
Dataset is not available.
This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. Also, the number of dispensed defined daily doses (DDDs) are presented. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Basic Registration of Persons (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands.
Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.
Data are broken down by medicine group, origin, age and sex.
Data available from 2020.
Status of the figures:
Figures for 2022 are provisional.
Changes as of December 20, 2023:
- Provisional figures for 2022 have been added, provisional figures of 2020 and 2021 have been made definite.
- Textual change: the description of drug group Y (Not filled in) has been replaced by Z (Not applicable). However, the underlying resources have remained the same. This category is assigned to products that do not have an ATC code according to the WHO ATC classification system.
When will new figures be published?
New figures will be published in the last quarter of 2024.
Description topics
- Persons with medicines, relative
- Number of persons to whom medicines are dispensed in the year concerned that are reimbursed under the statutory basic medical insurance, expressed as a percentage of the total population of the category concerned registered in the Basic Registration of Persons (BRP) in that year.
- Defined daily doses (DDD), relative
- Defined Daily Dose (DDD) is de door de WHO vastgestelde gemiddelde dagelijkse dosis van een geneesmiddel, wanneer het geneesmiddel wordt ingezet voor de hoofdindicatie, bij een onderhoudsbehandeling voor volwassenen. Deze definitie maakt het mogelijk om het gebruik van verschillende toedieningsvormen en verschillende middelen met elkaar te vergelijken.
WHO: World Health Organisation, Wereldgezondheidsorganisatie